Lessons learned from the prospective pravastatin pooling project

被引：1

作者：

Byington R.P. ^{[1
]}

Sacks F.M. ^{[1
]}

机构：

[1] Department of Public Health Sciences, Wake Forest University, School of Medicine, Winston-Salem, NC 27157-1063, Medical Center Boulevard

来源：

Current Atherosclerosis Reports | 2004年 / 6卷 / 5期

关键词：

Pravastatin; Scotland Coronary Prevention Study; Coronary Drug Project; Lipid Research Clinic Program; Coronary Incidence;

D O I：

10.1007/s11883-004-0048-z

中图分类号：

学科分类号：

摘要：

The Prospective Pravastatin Pooling (PPP) Project was a prospectively defined collaboration of three randomized, placebo-controlled, long-term, monotherapy (40 mg/d) trials of the lipid-lowering agent pravastatin. A pooled database of 19,768 participants with a mean of 5.2 years of follow-up was created, providing the investigators with over 100,000 patient-years of experience to address questions on total and cause-specific mortality, coronary incidence, stroke, and safety. One trial (West of Scotland Coronary Prevention Study) was primary prevention and two (Cholesterol and Recurrent Events and Long-term Intervention with Pravastatin in Ischemic Disease) were secondary prevention. Pravastatin was shown to safely reduce all-cause mortality, fatal and nonfatal coronary events, and stroke events in patients with a broad range of patient characteristics. Copyright © 2004 by Current Science Inc.

引用

页码：366 / 374

页数：8

共 29 条

[1]

The Coronary Drug Project: Design, methods, and baseline results. American Heart Association Monograph Number 38, Circulation, 47, SUPPL. I, (1973)

[2]

Clofibrate and niacin in coronary heart disease, JAMA, 231, pp. 360-381, (1975)

[3]

Canner P.L., Berge K.G., Wenger N.K., Et al., Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin, J. Am. Coll. Cardiol., 8, pp. 1245-1255, (1986)

[4]

A cooperative trial in the prevention of ischaemic heart disease using clofibrate, Br. Heart J., 40, pp. 1069-1118, (1978)

[5]

W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: Mortality follow-up, Lancet, 2, pp. 379-385, (1980)

[6]

WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: Final mortality follow-up, Lancet, 2, pp. 600-604, (1984)

[7]

The Coronary Primary Prevention Trial: Design and implementation, J. Chron. Dis., 32, pp. 609-631, (1979)

[8]

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease, JAMA, 251, pp. 351-364, (1984)

[9]

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering, JAMA, 251, pp. 365-374, (1984)

[10]

Frick M.H., Elo O., Haapa K., Et al., Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease, N. Engl. J. Med., 317, pp. 1237-1245, (1987)

← 1 2 3 →